The Motley Fool Investing Philosophy: We generally recommend investors buy shares of at least 25 stocks and hold them for at least 5 years. Learn More
| 1 Year | 5 Year | 5 Year Annualized | Since IPO | |
|---|---|---|---|---|
| PRLD | +384.06% | -94.13% | -43.26% | -85% |
| S&P | +19.17% | +69.21% | +11.09% | +102% |
Prelude Therapeutics, Inc. is a clinical-stage oncology company, which engages in the development of novel precision cancer medicines. It also focuses on the design and development of small molecule agents for cancer medicines. The company was founded by Krishna Vaddi in 2016 and is headquartered in Wilmington, DE.
| Q4 2025 | YOY Change | |
|---|---|---|
| Revenue | $5.64M | 41.0% |
| Gross Profit | $5.22M | 48.7% |
| Gross Margin | 92.59% | 4.8% |
| Market Cap | $164.18M | 134.0% |
| Market Cap / Employee | $2.08M | 0.0% |
| Employees | 79 | -39.7% |
| Net Income | -$16,457.00K | 42.7% |
| EBITDA | -$16,930.00K | 49.2% |
Currently no data to display
Currently no data to display.
Currently no data to display.
| Q4 2025 | YOY Change | |
|---|---|---|
| Net Cash | $35.26M | 182.6% |
| Inventory | 0 | 0.0% |
| Q4 2025 | YOY Change | |
|---|---|---|
| Long Term Debt | $15.05M | -1.8% |
| Short Term Debt | $2.74M | 1.6% |
| Q4 2025 | YOY Change | |
|---|---|---|
| Return On Assets | -62.81% | -6.7% |
| Return On Invested Capital | -51.97% | 15.0% |
| Q4 2025 | YOY Change | |
|---|---|---|
| Free Cash Flow | $23.12M | 211.2% |
| Operating Free Cash Flow | $23.12M | 211.4% |
| Metric | Q1 2025 | Q2 2025 | Q3 2025 | Q4 2025 | YoY Change |
|---|---|---|---|---|---|
| Price to Book | 0.32 | 0.44 | 1.07 | 2.80 | 525.24% |
| Price to Sales | 8.34 | 8.79 | 10.44 | 15.04 | 49.71% |
| Price to Tangible Book Value | 0.32 | 0.44 | 1.07 | 2.80 | 525.24% |
| Enterprise Value to EBITDA | 0.67 | -0.20 | -3.63 | -5.74 | -522.56% |
| Return on Equity | -81.4% | -96.3% | -104.0% | -99.5% | 44.10% |
| Total Debt | $17.92M | $17.92M | $17.85M | $17.79M | -1.31% |
No podcast episodes available.
No transcripts available.
Invest better with The Motley Fool. Get stock recommendations, portfolio guidance, and more from The Motley Fool's premium services.
